Digital Mammographic Imaging Screening Trial
 | This article needs additional citations for verification. (March 2024) |
The Digital Mammographic Imaging Screening Trial (DMIST) is a multi-institutional research study, beginning in 2001, on the efficacy for screening of full-field digital mammography (FFDM) compared to conventional film-screen mammography that was sponsored by the U.S. National Cancer Institute and performed by the American College of Radiology Imaging Network (ACRIN).[1]
The findings[2][3] that FFDM was not inferior to the existing technology, and potentially superior in younger women with dense breasts, has led to a rapid proliferation of digital systems in the US.[citation needed] On the other hand, women with dense breasts receive two to three times the amount of radiation during their imaging as dense breasts absorb more X-ray because of the density (difficulty of the X-ray to penetrate dense tissue).[citation needed]
References
[edit]- ^ Galen, Barbara; Staab, Edward; Sullivan, Daniel C.; Pisano, Etta D. "American College of Radiology Imaging Network: The Digital Mammographic Imaging Screening Trial—An Update" (PDF). National Cancer Institute. Retrieved 13 December 2023.
- ^ Pisano, Etta (27 October 2005). "Diagnostic Performance of Digital versus Film Mammography for Breast-Cancer Screening". New England Journal of Medicine. 353 (17). NEJM: 1773–1783. doi:10.1056/NEJMoa052911. PMID 16169887. Retrieved 11 February 2010.
- ^ Dershaw, D. David (2005). "Film or Digital Mammographic Screening?". New England Journal of Medicine. 353 (17): 1846–1847. doi:10.1056/NEJMe058253.